美股A股
StockGist
Back
10-Q2026-05-11· qwen-plus

HRTX · Heron Therapeutics, Inc.

0001193125-26-215755

SEC filing

Summary

Revenue was $34.7M (-10.8%) Gross Profit was $24.1M (-20.9%) Operating Income was -$4.8M (-251.1%) Net Income was -$8.1M (-407.8%)

Key takeaways

Full analysis

Liquidity and Capital Resources

Revenue and Gross Profit

Operating Income and Expenses

Outlook Context

Management noted that future cash requirements and the adequacy of available funds depend heavily on the Company’s ability to generate revenue and manage the scope and cost of commercial and R&D activities. Although Heron remains in compliance with Nasdaq continued listing requirements through the period covered by this report, management explicitly stated it cannot provide assurances that such compliance will continue in the future — underscoring material uncertainty around liquidity sustainability and regulatory standing.